Drugs /

anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of human autologous T-lymphocytes that are transduced with a lentiviral vector (LV) encoding an affinity-enhanced T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR LV-transduced autologous T-cells TAEST16001 recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells.

Clinical Trials

View Clinical Trials for anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001

Anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001, 3 are phase 1 (2 open).

CTAG1A Expression, CTAG1B Expression, and HLA-A*02:01 Positive are the most frequent biomarker inclusion criteria for anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001 clinical trials.

Breast carcinoma, hepatocellular carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Anti-Ny-Eso-1 Tcr Lv-Transduced Autologous T-Cells Taest16001
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Anti-Ny-Eso-1 Tcr Lv-Transduced Autologous T-Cells Taest16001
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
taest16001, taest 16001, ny-eso-1 antigen specific affinity-enhanced tcr transduced autologous t cells, anti-ny-eso-1 tcr transduced autologous t cells taest16001
Drug Target(s) [2]:
CTAG1B
NCIT ID [1]:
C147135

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.